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Introduction
Prenatal ultrasound is a powerful tool to detect structural
abnormalities associated with the fetus in trisomy 13
pregnancies [1–3]. This article provides a comprehen-
sive review of the prenatal sonographic markers of tri-
somy 13 in the first trimester, including fetal nuchal
translucency thickness, fetal heart rate, fetal nasal bone,
fetal tricuspid regurgitation, ductus venous flow, fetal
crown-rump length (CRL), fetal trunk and head volume,
fetal frontomaxillary facial (FMF) angle, gestational
sac volume (GSV) and umbilical cord diameter (UCD),
along with biochemical markers such as maternal serum
free β-human chorionic gonadotropin (hCG), maternal
serum pregnancy-associated plasma protein-A (PAPP-
A), maternal serum placental growth factor (PGF), and
the fetal and total cell-free DNA concentration in the
maternal circulation.
Maternal age is the most important risk factor
related to fetal trisomy 13 [4,5]. In the first trimester,
trisomy 13 is associated with increased maternal age,
increased fetal nuchal translucency (NT) thickness,
increased fetal heart rate (FHR), and decreased mater-
nal serum levels of free β-hCG and PAPP-A [6]. Fetuses
with trisomy 13 may present with major structural ab-
normalities such as omphalocele, holoprosencephaly
(HPE), megacystis and congenital heart defects [1,7],
smaller CRL and trunk and head volume [8–10], in-
creased FMF angle in the presence of HPE [11], smaller
GSV [12], smaller placental volume [13], reduced pla-
cental vascularization [14], a decreased level of maternal
serum PGF [15], absence of the nasal bone [16–18],
tricuspid regurgitation [19], and increased impedance
to flow in the ductus venosus [20] in the first trimester.
First-trimester maternal serum biochemistry in combi-
nation with maternal age, FHR, fetal NT thickness, fetal
structural abnormalities on ultrasound and other sono-
graphic markers such as fetal nasal bone, fetal tricuspid
regurgitation and fetal ductus blood flow aid early
diagnosis of trisomy 13.
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Fetal Nuchal Translucency Thickness
In the first trimester of pregnancy, the term nuchal
translucency refers to the ultrasound finding of subcuta-
neous collection of fluid behind the fetal neck irrespec-
tive of whether the collection of fluid is septated and
whether it is confined to the neck or envelopes the
whole fetus [21]. Increased fetal NT thickness refers to
the measurement of the vertical thickness in the mid-
sagittal section of the fetus that is equal to or above
the 95th centile of the reference range [22]. Fetal abnor-
malities are associated with the thickness of the fetal
NT rather than the appearance of fetal NT [21,23]. In
1998, the Fetal Medicine Foundation First Trimester
Screening Group suggested that the optional gesta-
tional age for the measurement of fetal NT is 11 gesta-
tional weeks to 13 gestational weeks and 6 days (13+6
weeks), with the corresponding minimum fetal CRL of
45 mm and the maximum CRL of 84 mm, and found
that the 95th centile of NT increased linearly with fetal
CRL from 2.1 mm at a CRL of 45 mm to 2.7 mm at a CRL
of 84 mm; by contrast, the 99th centile did not change
with CRL and it was approximately 3.5 mm [22].
Increased fetal NT thickness is associated with tri-
somy 13, trisomy 18, trisomy 21, Turner syndrome, other
sex chromosome abnormalities as well as many fetal
anomalies and genetic syndromes [24–27]. In a study of
20,804 pregnancies, including 164 cases of chromoso-
mal abnormalities, Pandya et al [28] found that NT
thickness increased significantly with CRL and that
increased NT thickness occurred in 66 of 86 fetuses
with Down syndrome (76.7%) and in 61 of 78 fetuses
with other chromosomal abnormalities (78.2%). In a
study of 1,015 pregnancies with increased NT thick-
ness, Pandya et al [29] found that the incidence of
Turner syndrome was ninefold higher and the incidence
of triploidy was eightfold higher than expected, but the
incidence of other sex chromosome abnormalities was
similar to that expected. Pandya et al [29] also found
that the observed numbers of trisomies 21, 18 and 13 in
fetuses with NT thicknesses of 3 mm, 4 mm, 5 mm and
≥ 6 mm were approximately three times, 18 times, 28
times and 36 times higher, respectively, than the num-
bers expected on the basis of maternal age. In a study of
42,619 pregnancies in 20 British centers, Snijders et al
[30] found that the incidence of increased NT thickness
> 95th centile for trisomy 21, trisomy 18, trisomy 13,
other trisomies, Turner syndrome, other sex aneuploidies
and triploidy was 111 of 147 (75.5%), 47 of 60 (78.3%),
14 of 17 (82.4%), 4 of 6 (66.7%), 17 of 18 (94.4%), 4 of
12 (33.3%) and 6 of 9 fetuses (66.7%), respectively. In a
study of 91,091 singleton pregnancies, including 106
fetuses with trisomy 18, Sherod et al [31] found that
the incidence of increased NT thickness >95th centile for
trisomy 18 was 84 in 106 (79.2%), and that trisomy 18
was associated with early onset intrauterine growth
restriction in 21 of 98 fetuses (21.4%), decreased FHR 
in 6 of 58 fetuses (10.3%) and exomphalos in 22 of 
84 fetuses (26.2%). In a study of 100,311 singleton
pregnancies, including 46 fetuses with trisomy 13,
Snijders et al [32] found that the incidence of increased
NT thickness > 95th centile for trisomy 13 was 33 of 46
fetuses (71.7%) and that trisomy 13 was associated
with normal fetal growth in 41 of 46 fetuses (89.1%),
increased FHR in 16 of 25 fetuses (64%), HPE in 11 of 46
fetuses (23.9%) and exomphalos in 3 of 46 fetuses
(6.5%). In a study of 11,315 pregnancies, including
2,168 fetuses with chromosomal abnormalities, Kagan
et al [33] found that the overall incidence of chromo-
somal abnormalities increased with NT thickness from
7.1% (507/7,109) for 95th centile for CRL –3.4mm to
20.1% (423/2,101) for 3.5–4.4 mm, 45.8% (321/701)
for 4.5–5.4 mm, 50.1% (219/437) for 5.5–6.4 mm,
70.6% (218/309) for 6.5–7.4 mm, 70.8% (148/209) for
7.5–8.4 mm, 75% (126/168) for 8.5–9.4 mm, 84.1%
(74/88) for 9.5–10.4 mm, 70.3% (45/64) for 10.5–
11.4 mm and 70.7% (87/123) for ≥ 11.5 mm. Kagan 
et al [33] also found that in the majority of fetuses with
trisomy 21, the NT thickness was < 4.5 mm, whereas in
the majority of fetuses with trisomies 13 and 18, it was
4.5–8.4 mm, and in Turner syndrome, it was ≥ 8.5 mm.
Fetal Heart Rate
Various studies have shown that FHR increases from
110 beats/min (bpm) at week 5 of gestation to
170 bpm at week 9 of gestation, and then gradually
decreases to 150 bpm by week 14 of gestation, which
suggests functional maturation of the parasympa-
thetic system [34–36]. In normal pregnancies, there is
a decrease in FHR between weeks 10 and 14 of gesta-
tion [37,38]. In a study of 6,903 normal singleton
pregnancies, Hyett et al [37] found that FHR de-
creased from a mean value of 171 bpm at the week 10
of gestation to 156 bpm at week 14, and there was no
significant association between FHR and fetal NT
thickness. Shulman et al [39] reported prenatal diag-
nosis of trisomy 13 distinguished by persistent fetal
tachycardia. The patient was a 34-year-old, gravida 3,
para 2, woman who was referred for counseling and
chorionic villus sampling because of advanced mater-
nal age and a child with Down syndrome. Ultrasonogra-
phy showed a singleton at 9.7 weeks of gestation with
no fetal or placental structural abnormalities, except
for persistent fetal tachycardia with a FHR of 190 bpm.
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The patient underwent chorionic villus sampling (CVS)
at 10 weeks of gestation when FHR was measured at
190 bpm before and after CVS. CVS revealed trisomy
13, and the pregnancy was terminated. Trisomy 13
was confirmed in cultured mesenchymal core cells and
fetal tissue. In a study of 25,000 normal singleton
pregnancies, Liao et al [38] found that the FHR de-
creased from a mean value of 170 bpm at a CRL of
35 mm to 150 bpm at a CRL of 84 mm.
In first-trimester studies, fetal tachycardia was asso-
ciated with trisomy 13, trisomy 21 and Turner syndrome,
and fetal bradycardia was associated with trisomy 18
and triploidy [37,38]. In a study of 85 pregnancies with
trisomy 21 fetuses, 34 with trisomy 18, 16 with trisomy
13, 19 with Turner syndrome and eight with triploidy,
Hyett et al [37] found that the FHR was significantly
higher in trisomy 21, trisomy 13 and Turner syndrome
fetuses and significantly lower in trisomy 18 and triploidy
fetuses than that in the normal group. In a study of
554 pregnancies with trisomy 21 fetuses, 219 with tri-
somy 18, 95 with trisomy 13, 50 with triploidy, 115
with Turner syndrome and 28 with sex chromosome
abnormalities other than Turner syndrome, Liao et al
[38] found that FHR was significantly higher in trisomy
21, trisomy 13 and Turner syndrome fetuses and signif-
icantly lower in trisomy 18 and triploidy fetuses than
that in the normal group. Furthermore, the FHR in other
sex chromosome abnormalities was not significantly
different from that in the normal group. The authors
also found that the FHR was above the 95th centile of
the normal range in 10%, 52% and 67% of the fetuses
with trisomy 21, Turner syndrome and trisomy 13,
respectively, and that FHR was below the 5th centile of
the normal range in 19% and 30% of the fetuses with
trisomy 18 and triploidy, respectively.
The pathogenesis of fetal tachycardia in trisomy 13
includes structural cardiac abnormalities and a com-
pensatory mechanism to increase cardiac output in
fetuses with left heart obstruction [37,40,41]. In a study
of 17 fetuses with trisomy 13 in the first trimester,
Hyett et al [41] found that 15 of 16 hearts had cardiac
abnormalities, which included ventricular septal de-
fects, valvular defects and agenesis of the pulmonary
valve. Furthermore, 15 of 15 great vessels had anom-
alies, including a decrease in both the aortic valve and
aortic isthmus, an increase in the ratio of aortic valve
to aortic isthmus and of ductus arteriosus to aortic
isthmus, while three of 15 fetuses had truncus arteriosus.
In fetuses with trisomy 13, the compensatory mechanism
to increase cardiac output in those with narrowing of
the outflow tract from the left ventricle is likely medi-
ated by baroreceptor activity in the aortic arch [37,
38,40–42]. The same mechanism may also be involved
in tachycardia in fetuses with trisomy 21 or Turner syn-
drome [37]. In fetuses with trisomy 18 or triploidy,
bradycardia may be related to early onset of intrauter-
ine growth restriction, severe developmental delay, and
a preterminal event in intrauterine fetal death [37,38].
Papageorghiou et al [42] demonstrated that at the
ultrasound scan performed at weeks 11–13+6, trisomy
13 was associated with easily detectable major structural
anomalies, high NT thickness, and tachycardia. The
authors performed a study of 181 fetuses with trisomy
13 to examine the sonographic features of trisomy 13 at
weeks 11–13+6 of gestation. They found HPE, omphalo-
cele and/or megacystis in 92 fetuses (50.8%), FHR above
the 95th centile in 129 fetuses (71.3%), FHR above the
99th centile in 93 fetuses (51.4%), and NT thickness
above the 95th centile in 141 fetuses (77.9%). They esti-
mated that including FHR in NT screening improved
the detection rate of trisomy 13 by approximately 5%.
Papageorghiou et al [42] found that in trisomy 13
fetuses, the mean delta FHR was significantly higher
than normal (mean, 15 bpm above the normal; 95%
confidence interval, CI, 14–16 bpm; p < 0.0001), and
the likelihood ratio for trisomy 13 increased exponen-
tially with delta FHR. Papageorghiou et al [42] also
found that when the FHR was > 20 bpm above the nor-
mal mean for CRL (approximately 185 bpm at a CRL of
45 mm and 175 bpm at a CRL of 85 mm), the likelihood
ratio for trisomy 13 was 495.4 (95% CI, 285.9–858.4) in
31.5% (57/181) of trisomy 13 fetuses versus only 0.06%
of normal controls. Papageorghiou et al [42] concluded
that, at the 11–13+6-week sonographic screening, the
measurement of fetal NT and FHR, and the examina-
tion of HPE, omphalocele and megacystis, can identify
over 90% of fetuses with trisomy 13.
Kagan et al [6] showed a significant change in FHR
in trisomy 13 fetuses but a very small change in FHR in
trisomy 21 and trisomy 18 fetuses compared with nor-
mal controls. In their study, in 395 fetuses with trisomy
21, the mean FHR was above the appropriate mean for
gestation in unaffected pregnancies by about 1 bpm and
there was no evidence of a change with gestation. In
122 fetuses with trisomy 18, the mean FHR was below
the appropriate mean for gestation in unaffected preg-
nancies by about 3 bpm and there was no evidence of
a change with gestation. In 61 fetuses with trisomy 13,
the mean FHR was above the appropriate mean for ges-
tation in unaffected pregnancies by about 20 bpm at 11
weeks of gestation, 17 bpm at 12 weeks of gestation and
14 bpm at 13 weeks of gestation. Kagan et al [6] found
that in fetuses with trisomy 13, the FHR was above the
95th and 99th centiles of unaffected pregnancies in 85.2%
and 62.3% of fetuses, respectively. By contrast, in fetuses
with trisomy 21, the FHR was above the 95th and 99th
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centiles of unaffected pregnancies in 13.7% and 6.3%
of cases, respectively, and, in fetuses with trisomy 18, the
FHR was below the 5th and 1st centiles of unaffected
pregnancies in 17.2% and 9.2% of fetuses, respectively.
Kagan et al [6] also showed that the inclusion of
FHR with first-trimester maternal serum biochemistry
in combination with maternal age and fetal NT thick-
ness improved the detection rate of trisomy 13 but did
not improve the detection rate of trisomy 18 or trisomy
21. According to their study, at a 0.2% false-positive
rate, the estimated detection rates of trisomy 13 using
the risk algorithm for trisomy 13 based on maternal
age+ fetal NT, maternal age+ fetal NT+ serum biochem-
istry, and maternal age + fetal NT + serum biochem-
istry + FHR were 45%, 77% and 87%, respectively. At a
0.2% false-positive rate, the estimated detection rates of
trisomy 18 using the risk algorithm for trisomy 18 based
on maternal age + fetal NT, maternal age + fetal NT +
serum biochemistry and maternal age+ fetal NT+ serum
biochemistry + FHR were 61%, 93% and 91%, respec-
tively. At a 3% false-positive rate, the estimated detec-
tion rates of trisomy 21 using the risk algorithm for
trisomy 21 based on maternal age + fetal NT, maternal
age + fetal NT + serum biochemistry, and maternal
age + fetal NT + serum biochemistry + FHR were 75%,
89% and 90%, respectively.
Fetal Nasal Bone
The fetal nasal bone should be examined at weeks
11+0–13+6 of gestation on a midsagittal section of the
fetal profile, with software adjusting for potential con-
founding factors [16–18]. The incidence of fetuses with
an absent nasal bone decreases with fetal CRL, increases
with NT thickness, and is substantially higher in fetuses
of Afro-Caribbean origin than in Caucasians [17,18].
Absence of the nasal bone is associated with aneu-
ploidy. In a study that evaluated the incidence of nasal
hypoplasia among fetuses of southern Chinese women,
Wong et al [43] found that the incidence of an absent
nasal bone in fetuses with a normal karyotype was 1 in
114 fetuses (0.88%), which is comparable with Cau-
casian fetuses. This suggests that assessing the ossifi-
cation of the fetal nasal bone can be used in southern
Chinese women as a supplementary screening test for
Down syndrome. Prefumo et al [44] also showed that
first-trimester ultrasound failed to demonstrate the
fetal nasal bone twice as often in mothers of African
origin compared with Caucasians, but the failure to visu-
alize the fetal nasal bone was not significantly higher in
women of Asian origin than in women of Caucasian ori-
gin. In a meta-analysis of 15,822 fetuses included in the
studies by Cicero et al [16–18], Otano et al [45], Orlandi
et al [46], Senat et al [47], Viora et al [48], Wong et al
[43], Zoppi et al [49] and Nicolaides [27], with suc-
cessful examination in 15,413 of 15,822 (97.4%) of all
pregnancies, absence of the nasal bone was found in
176 of 12,652 (1.4%) chromosomally normal fetuses
and in 274 of 397 (69%) fetuses with trisomy 21. Cicero
et al [18] showed that the incidence of an absent nasal
bone at weeks 11+0–13+6 of gestation in fetuses with
trisomy 21, trisomy 18, trisomy 13, triploidy, Turner
syndrome, other sex chromosome abnormalities (XXY,
XXX and XYY) and other aneuploidies was 229 of 333
(68.8%), 68 of 124 (54.8%), 13 of 38 (34.2%), 0 of 19
(0%), 5 of 46 (10.9%), 1 of 20 (5.0%) and 8 of 48
fetuses (16.7%), respectively.
Fetal Tricuspid Regurgitation
Fetal tricuspid regurgitation is measured by pulsed-
wave Doppler on an apical four-chamber view at weeks
11+0–13+6 of gestation. Fetal tricuspid regurgitation is
related to an increased risk of aneuploidy [19,50–52].
Falcon et al [52] reported tricuspid regurgitation in 77
of 114 fetuses with trisomy 21 (67.5%), 14 of 42 fetuses
with trisomy 18 (33.3%), and 58 of 1,323 euploid fetuses
(4.4%). Kagan et al [19] reported tricuspid regurgita-
tion in 68 of 122 fetuses with trisomy 21 (55.5%), 12 of
36 fetuses with trisomy 18 (33.3%), six of 20 fetuses with
trisomy 13 (30%), three of eight fetuses with Turner
syndrome (37.5%), and 181 of 19,614 euploid fetuses
(0.9%).
Ductus Venosus Flow
Abnormal ductus venosus flow with the presence of a
reversed a wave is caused by increased impedance to
flow in the ductus venosus and is related to an increased
risk of aneuploidy [20,53–59]. In a meta-analysis of the
incidence of abnormal ductus venosus flow in the first
trimester in euploid fetuses (n=6,790), and in those with
trisomy 21 (n = 185), trisomy 18 (n = 28), trisomy 13
(n =11), Turner syndrome (n =13) and other chromoso-
mal abnormalities (n=18), Maiz et al [20] reported that
abnormal ductus venosus flow was observed in 5.2% of
euploid fetuses and in 70.8%, 89.3%, 81.8%, 76.9% and
55.6% of the fetuses with trisomy 21, trisomy 18, trisomy
13, Turner syndrome and other chromosomal abnor-
malities, respectively. Maiz et al [20], in their own study
at weeks 11+0–13+6 weeks of gestation, showed that
the incidence of abnormal ductus venosus flow was
observed in 3.2% (622/19,614) of euploid fetuses and
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in 66.4% (81/122), 58.3% (21/36), 55.0% (11/20) and
75.0% (6/8) of the fetuses with trisomy 21, trisomy 18,
trisomy 13 and Turner syndrome, respectively.
Screening for Aneuploidy by Maternal
Age, Fetal NT, Maternal Serum Free 
-hCG, Maternal Serum PAPP-A and
FHR, with Fetal Nasal Bone, Tricuspid
Regurgitation or Ductus Venosus Flow
Trisomy 21 is characterized by increased maternal age,
increased NT thickness, increased maternal serum free
β-hCG, and decreased maternal serum PAPP-A. Mean-
while, trisomy 18 is characterized by increased maternal
age, increased NT thickness, decreased FHR, decreased
maternal serum free β-hCG, and decreased maternal
serum PAPP-A. Trisomy 13 is characterized by increased
maternal age, increased NT thickness, increased FHR,
decreased maternal serum free β-hCG, and decreased
maternal serum PAPP-A [4,5,22,32,37,38,42,60–68].
Spencer et al [61] reported a median of 0.506 mul-
tiples of the median (MoM) for maternal serum free 
β-hCG and a median of 0.248 MoM for maternal serum
PAPP-A in 42 cases of trisomy 13 pregnancies at weeks
10–14 of gestation. Screening for fetal trisomies in a one-
step clinic for assessment of risk for fetal abnormalities
(OSCAR) program with fetal NT and maternal serum
free β-hCG and PAPP-A at 10–14 weeks of gestation can
identify about 90% of trisomy 21 pregnancies at a false-
positive rate of 5% [69], about 86% of trisomy 18 preg-
nancies at a false-positive rate of 0.5% [60], and about
84% of trisomy 13 pregnancies at a false-positive rate
of 0.1% [61]. Spencer and Nicolaides [63] also used a
first-trimester trisomy 13/trisomy 18 risk algorithm that
combined fetal NT thickness, maternal serum free β-
hCG and PAPP-A to examine 45 cases of trisomy 13 and
59 cases of trisomy 18 at 11–14 weeks of gestation.
That study showed a median of 2.819 MoM for NT, a
median of 0.375 MoM for maternal serum free β-hCG,
and a median of 0.201 MoM for maternal serum
PAPP-A in the trisomy 13/trisomy 18 group. Spencer
and Nicolaides [63] predicted that the combined tri-
somy 13/trisomy 18 algorithm can identify 95% of fe-
tuses with trisomy 13 and trisomy 18 with a risk cut-
off of 1 in 150 and a false-positive rate of 0.3%. In a
study of 12,339 women with singleton pregnancies pre-
senting at 10–14 weeks of gestation who were offered
a combination of maternal serum free β-hCG and
PAPP-A, and fetal NT thickness, with the option of an
invasive diagnostic test at an estimated risk of ≥1 in 300
of carrying a fetus with trisomy 21, trisomy 18 or tri-
somy 13, Spencer et al [62] found that the uptake of
first-trimester screening and invasive testing in the
higher-risk group was 97.5% and 77%, respectively, and
that the detection rates of trisomy 21, trisomy 18, trisomy
13, Turner syndrome, other sex chromosome abnor-
malities, triploidy and all aneuploidies were 23 of 25
(92%), 11 of 11 (100%), 4 of 4 (100%), 4 of 4 (100%),
2 of 2 (100%), 5 of 5 (100%) and 49 of 51 fetuses
(96.1%), respectively.
Kagan et al [65] performed a prospective screening
program for aneuploidy in singleton pregnancies at
weeks 11+0–13+6 of gestation that included 56,376 nor-
mal cases, 395 with trisomy 21, 122 with trisomy 18,
and 61 with trisomy 13. They found that at a 3.1% false-
positive rate using algorithms developed to calculate
patient-specific risks for each of the three trisomies
based on maternal age, fetal NT thickness, FHR, and
maternal serum free β-hCG and PAPP-A, the estimated
detection rates for trisomies 21, 18 and 13 were 91%,
97% and 94%, respectively. In a prospective screening
program for aneuploidy in singleton pregnancies at
weeks 11+0–13+6 of gestation, including 19,614 pregnan-
cies with a normal karyotype or delivery of a phenotyp-
ically normal baby (euploid group), 122 with trisomy 21,
36 with trisomy 18, 20 with trisomy 13 and eight with
Turner syndrome, Kagan et al [70] found that with a
fixed risk cut-off of 1 in 100 for the total risk for tri-
somies 21, 18 and 13 and Turner syndrome, a standard-
ized false-positive rate of 3.0%, the detection rates for
trisomies 21, 18 and 13 and Turner syndrome 91%,
100%, 100% and 100%, respectively, with a screening
test that included maternal age, fetal NT thickness, FHR,
and maternal serum free β-hCG and PAPP-A. Kagan et al
[70] also found that including nasal bone assessment
in all pregnancies before the combined test reduced the
false-positive rate to 2.5% without changing the detec-
tion rate. Kagan et al [19] also found that with the
inclusion of the assessment of tricuspid flow to detect
tricuspid regurgitation in all pregnancies before the com-
bined test, the detection rates of trisomy 21, trisomy 18,
trisomy 13 and Turner syndrome were 96%, 92%, 100%
and 100%, respectively.
In a prospective screening program for aneuploidy in
singleton pregnancies at weeks 11+0–13+6 of gestation,
including 19,614 pregnancies with euploid fetuses, 122
with trisomy 21, 36 with trisomy 18, 20 with trisomy 13
and eight with Turner syndrome, Maiz et al [20] found
that including ductus venosus flow with maternal age,
fetal NT thickness, FHR, and maternal serum free β-hCG
and PAPP-A would detect 96%, 92%, 100% and 100% of
trisomies 21, 18 and 13 and Turner syndrome, respec-
tively, at a false-positive rate of 3.0%. The same detec-
tion rates were achieved with the two-stage strategy, in
which the first-stage screening using the combined test
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in all patients was followed by second-stage assessment
of the a wave in those with an intermediate risk of 1 in
51 to 1 in 1,000 after the first stage, at a false-positive
rate of 2.6%; assessment of ductus venosus flow was
required in only 15% of the total population.
Fetal Crown-rump Length, and Fetal
Trunk and Head Volume
Compared with euploid babies, the birth weight deficit
in aneuploid babies is about 10–15% for trisomy 21 and
Turner syndrome, about 20% for trisomy 13, and about
30% for trisomy 18 [71,72]. In the first trimester, ges-
tational age and fetal growth are essentially assessed
by two-dimensional ultrasound measurement of CRL.
Drugan et al [73] found a lag of at least 7 days in CRL-
based estimates of gestational age in 4.3% of fetuses
with chromosomal abnormalities, compared with 1.7%
of normal fetuses in the first trimester, and suggested
that the smaller than expected first-trimester fetus is at
risk for chromosomal abnormalities. Kuhn et al [74]
measured CRL in 135 chromosomally abnormal fetuses
and 700 chromosomally normal fetuses at 10–13 weeks
of gestation. They found that the median CRL in fetuses
with trisomy 18 (n = 32) was significantly reduced and
that the median CRLs in fetuses with trisomy 21 (n=72),
trisomy 13 (n =11), 45,X (n =5), 47,XXX (n =6), 47,XXY
(n=6) and triploidy (n=3) were not shorter than normal.
Schemmer et al [75] measured CRLs in 196 chromo-
somally abnormal fetuses and in 1,929 chromosomally
normal fetuses in the first trimester and found that the
mean CRLs and growth rates were significantly reduced
in fetuses with trisomy 18 (n = 49), trisomy 13 (n = 19)
and triploidy (n =8). However, these growth parameters
were not significantly reduced in fetuses with trisomy
21 (n = 92), Turner syndrome (n = 8) or other sex chro-
mosomal abnormalities (n = 20). Bahado-Singh et al
[76] found that there was significant CRL shortening in
trisomy 18 fetuses with observed/expected values
≤ 0.80 (odds ratio, 13.78; 95% CI, 5.64–33.88; p <
0.000001), there was evidence of CRL shortening in
trisomy 13 fetuses with observed/expected values ≤0.90
(odds ratio, 3.64; 95% CI, 1.08–12.96; p < 0.03), and
there was no significant CRL shortening in trisomy 21
fetuses with observed/expected values ≤ 0.92 (odds
ratio, 0.86; 95% CI, 0.5–1.47; p = 0.6).
With the introduction of three-dimensional ultra-
sound, the measurement of fetal trunk and head volume
offers a new approach for the early diagnosis of fetal
growth restriction [8–10]. Falcon et al [9] performed a
study of fetal trunk and head volume in 500 euploid
fetuses, 72 trisomy 21 fetuses, 29 trisomy 18 fetuses,
14 trisomy 13 fetuses, 14 Turner syndrome fetuses and
11 triploid fetuses at weeks 11+0–13+6 of gestation.
They found that compared with the normal group,
fetuses with trisomy 21 and Turner syndrome had sim-
ilar CRL for gestational age (p = 0.335 and p = 0.317,
respectively), and the fetal trunk and head volumes
were about 10–15% lower (p < 0.001 and p = 0.004,
respectively). However, in trisomy 18, trisomy 13 and
triploidy fetuses, the deficit in CRL was less than 15%
(p < 0.001), while the deficit in fetal trunk and head
volume was about 45% (p <0.001). Falcon et al [10]
also calculated the fetal head-to-trunk volume ratio in
chromosomally abnormal fetuses at weeks 11+0–13+6
of gestation and found that in trisomy 13, trisomy 18
and triploidy fetuses, the growth restriction was asym-
metrical with the trunk being more severely compro-
mised than the head. By contrast, in trisomy 21 and
Turner syndrome, the growth restriction was symmetri-
cal with the trunk and head being equally affected.
Fetal Frontomaxillary Facial Angle
Measurement of the fetal FMF angle is a sonographic
method used to define the relative portion of the maxilla
to the forehead at weeks 11+0–13+6 of gestation [11,
77–79]. Fetuses with trisomy 21 and trisomy 18 are
associated with midfacial hypoplasia and a significantly
larger FMF angle than that in euploid fetuses at weeks
11+0–13+6 of gestation [11,77–79]. However, in
fetuses with trisomy 13, the FMF angle at weeks
11+0–13+6 of gestation is only increased in cases with
HPE [11]. In a study of 23 fetuses with trisomy 13,
Borenstein et al [11] found that in 12 fetuses with HPE,
the FMF angle was above the 95th centile of the normal
range in 10 fetuses and was not significantly different
from the normal range in 11 fetuses without HPE.
Gestational Sac Volume
In a study of the association between chromosomal
defects and GSV measured by three-dimensional ultra-
sound at weeks 11–13+6 of gestation, Falcon et al [12]
found that the mean GSV for gestational age in fetuses
with trisomy 21 (n = 45), trisomy 18 (n = 17) and Turner
syndrome (n = 10) was not significantly different from
that of chromosomally normal fetuses (n=417). By con-
trast, GSV was smaller in those with trisomy 13 (n = 6)
and triploidy (n = 5) than in chromosomally normal
fetuses. Falcon et al [12] also found that the mean GSV
for CRL was significantly larger in trisomy 18, smaller 
in trisomy 13 and triploidy fetuses, and was similar to
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normal values in trisomy 21 and Turner syndrome.
Meanwhile, the mean CRL for gestational age was sig-
nificantly smaller than normal in trisomy 18, trisomy
13 and triploidy fetuses. Falcon et al [12] concluded
that in fetuses with trisomy 13 and triploidy, the small
GSV may be due to early-onset growth restriction and
reduced amniotic fluid, and that in trisomy 18, the large
GSV may be due to interference with fetal swelling by
the associated congenital anomalies.
Umbilical Cord Diameter
Ghezzi et al [80] first suggested UCD at 10–14 weeks of
gestation as an ultrasound marker for fetal aneuploidy
based on the findings that the proportion of fetuses with
an UCD above the 95th centile was higher in fetuses with
chromosomal abnormalities than in normal fetuses (5/17
vs. 39/767; p <0.01). Ghezzi et al [80] hypothesized that
the underlying pathophysiologic mechanisms leading to
an increase in UCD might be associated with increased
NT thickness, such as changes in the extracellular matrix
components or fetal venous congestion. Axt-Fliedner
et al [81] found that at 11–14 weeks of gestation, fetuses
with chromosomal abnormalities were more likely to
have an UCD above the 95th centile. In their study, the
proportion of fetuses with UCD above the 95th centile
for CRL was higher in aneuploid fetuses compared with
euploid fetuses (5/14 vs. 13/285; p <0.005). However,
Rembouskos et al [82] found that the UCD in trisomy
21 fetuses (n = 97) was significantly lower than normal
(n=1,150), but in fetuses with trisomy 18 (n=42), Turner
syndrome (n =18), trisomy 13 (n=6), triploidy (n=6) or
47,XXY (n = 4), there was no significant difference from
the normal value.
Maternal Serum Placental Growth Factor
The first-trimester maternal serum level of PGF was
found to be lower in pregnancies with trisomy 13 than in
pregnancies with euploid fetuses [15]. In a study of 45
pregnancies with trisomy 21, 45 with trisomy 18 and
493 with normal results at weeks 10–13 of gestation,
Spencer et al [83] found that the median maternal
serum PGF concentration in the trisomy 21 group was
1.26 MoM, which was significantly higher than that in
the control group. Furthermore, the median maternal
serum PGF concentration in the trisomy 18 group was
0.889 MoM, which was lower than that in the control
group, but did not reach significance. Zaragoza et al
[15] performed a study of 90 pregnancies with trisomy
21, 28 with trisomy 18, 19 with trisomy 13, 28 with
Turner syndrome, 10 with triploidy, and 609 with
euploid results at weeks 11+0–13+6 of gestation. They
found that the median values in pregnancies with tri-
somy 21, trisomy 18, trisomy 13, Turner syndrome and
triploidy were 0.707 MoM, 0.483 MoM, 0.404 MoM,
0.534 MoM and 0.531 MoM, respectively, which were
significantly lower than the value of 0.991 MoM in the
euploid group. Zaragoza et al [15] suggested that incor-
porating PGF in the first-trimester combined screening
for trisomy 21 might improve the detection rates of other
major aneuploidies because of the significantly lower
serum levels of PGF in trisomy 18, trisomy 13, Turner
syndrome and triploid pregnancies.
Fetal and Total Cell-free DNA
Concentrations in Maternal Circulation
Lo et al [84] first reported significantly higher fetal cell-
free DNA concentrations in the plasma of pregnant
women carrying fetuses with trisomy 21 (n = 13) com-
pared with those carrying normal fetuses (n = 37) at
17–18 weeks of gestation. Zhong et al [85] reported
significantly elevated fetal cell-free DNA in maternal
plasma in pregnancies with trisomy 21 (n = 15) and tri-
somy 13 (n =3) fetuses and a nonsignificant elevation in
trisomy 18 (n =6) compared with the normal (n =29) at
14+4 weeks of gestation. Ohashi et al [86] reported that
the levels of maternal serum fetal cell-free DNA in preg-
nancies with trisomy 21 (n = 5) and trisomy 18 (n = 3)
fetuses were not significantly different from those in
pregnancies with normal fetuses (n=55) at 15–17 weeks
of gestation. Hromadnikova et al [87] reported no sig-
nificant differences in maternal plasma fetal cell-free
DNA or total cell-free DNA levels in pregnancies with
normal (n = 13) and trisomy 21 (n = 11) fetuses at 20
weeks of gestation. Lee et al [88] reported significantly
elevated fetal cell-free DNA in maternal serum in preg-
nancies with trisomy 21 (n = 11) fetuses compared with
normal fetuses (n = 55) at 15–19 weeks of gestation.
Spencer et al [89] reported that the maternal serum con-
centration of fetal cell-free DNA was not significantly
different, whereas the maternal serum concentration
of total cell-free DNA was significantly elevated in
pregnancies with trisomy 21 (n = 10) fetuses compared
with normal fetuses (n = 10) at 15 weeks of gestation.
Wataganara et al [90] reported that maternal serum
fetal cell-free DNA levels were increased in fetuses with
trisomy 13 (n = 5) but not trisomy 18 (n = 5) compared
with normal fetuses (n=24) at 15–20 weeks of gestation.
Gerovassili et al [91] found that the first-trimester
maternal plasma levels of fetal cell-free DNA were not
significantly different between pregnancies with normal
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fetuses (n = 238) and pregnancies with trisomy 21
(n = 38), trisomy 18 (n = 9), trisomy 13 (n = 4) and
triploidy (n = 5) fetuses. Similarly, they reported no dif-
ferences between the first-trimester maternal plasma
levels of total cell-free DNA in pregnancies with normal
fetuses (n = 264) and pregnancies with trisomy 21
(n =72), trisomy 18 (n=24), trisomy 13 (n=12), Turner
syndrome (n = 16) and triploidy (n = 8) fetuses. Gero-
vassili et al [91] suggested that the fetal cell-free DNA is
not an ideal prognostic marker for chromosomal abnor-
malities in first-trimester pregnancies.
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